|
1
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition.
International Agency for Research on Cancer; Lyon: pp. 130–139.
2008
|
|
2
|
Wilson MB, Schreiner SJ, Choi HJ, Kamens J
and Smithgall TE: Selective pyrrolo-pyrimidine inhibitors reveal a
necessary role for Src family kinases in Bcr-Abl signal
transduction and oncogenesis. Oncogene. 21:8075–8088. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lionberger JM, Wilson MB and Smithgall TE:
Transformation of myeloid leukemia cells to cytokine independence
by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem.
275:18581–18585. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Hare T, Zabriskie MS, Eiring AM and
Deininger MW: Pushing the limits of targeted therapy in chronic
myeloid leukaemia. Nat Rev Cancer. 12:513–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eide CA and O'Hare T: Chronic myeloid
leukemia: Advances in understanding disease biology and mechanisms
of resistance to tyrosine kinase inhibitors. Curr Hematol Malig
Rep. 10:158–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Azam M, Seeliger MA, Gray NS, Kuriyan J
and Daley GQ: Activation of tyrosine kinases by mutation of the
gatekeeper threonine. Nat Struct Mol Biol. 15:1109–1118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cortes JE, Kantarjian H, Shah NP, Bixby D,
Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, et al:
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
N Engl J Med. 367:2075–2088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cortes JE, Kim DW, Pinilla-Ibarz J, le
Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ,
Talpaz M, et al: A phase 2 trial of ponatinib in Philadelphia
chromosome-positive leukemias. N Engl J Med. 369:1783–1796. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Redaelli S, Piazza R, Rostagno R,
Magistroni V, Perini P, Marega M, Gambacorti-Passerini C and
Boschelli F: Activity of bosutinib, dasatinib, and nilotinib
against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol.
27:469–471. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Redaelli S, Mologni L, Rostagno R, Piazza
R, Magistroni V, Ceccon M, Viltadi M, Flynn D and
Gambacorti-Passerini C: Three novel patient-derived BCR/ABL mutants
show different sensitivity to second and third generation tyrosine
kinase inhibitors. Am J Hematol. 87:E125–E128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barrett AJ and Ito S: The role of stem
cell transplantation for chronic myelogenous leukemia in the 21st
century. Blood. 125:3230–3235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saussele S and Silver RT: Management of
chronic myeloid leukemia in blast crisis. Ann Hematol. 94 Suppl
2:S159–S165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rix LL Remsing, Rix U, Colinge J,
Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent
P, Augustin M, et al: Global target profile of the kinase inhibitor
bosutinib in primary chronic myeloid leukemia cells. Leukemia.
23:477–485. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cortes JE, Kantarjian HM, Brummendorf TH,
Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S,
Volkert A, et al: Safety and efficacy of bosutinib (SKI-606) in
chronic phase Philadelphia chromosome-positive chronic myeloid
leukemia patients with resistance or intolerance to imatinib.
Blood. 118:4567–4576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gambacorti-Passerini C, Brümmendorf TH,
Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian
HM, Khoury HJ, Zaritskey A, et al: Bosutinib efficacy and safety in
chronic phase chronic myeloid leukemia after imatinib resistance or
intolerance: Minimum 24-month follow-up. Am J Hematol. 89:732–742.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khoury HJ, Cortes JE, Kantarjian HM,
Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A,
Countouriotis A, Besson N, Leip E, et al: Bosutinib is active in
chronic phase chronic myeloid leukemia after imatinib and dasatinib
and/or nilotinib therapy failure. Blood. 119:3403–3412. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kantarjian HM, Cortes JE, Kim DW, Khoury
HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E,
Kelly V, et al: Bosutinib safety and management of toxicity in
leukemia patients with resistance or intolerance to imatinib and
other tyrosine kinase inhibitors. Blood. 123:1309–1318. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cortes JE, Kim DW, Kantarjian HM,
Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C,
Gogat K, Countouriotis AM and Gambacorti-Passerini C: Bosutinib
versus imatinib in newly diagnosed chronic-phase chronic myeloid
leukemia: Results from the BELA trial. J Clin Oncol. 30:3486–3492.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brümmendorf TH, Cortes JE, de Souza CA,
Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis AM and
Gambacorti-Passerini C: Bosutinib versus imatinib in newly
diagnosed chronic-phase chronic myeloid leukaemia: Results from the
24-month follow-up of the BELA trial. Br J Haematol. 168:69–81.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakaseko C, Takahashi N, Ishizawa K,
Kobayashi Y, Ohashi K, Nakagawa Y, Yamamoto K, Miyamura K, Taniwaki
M, Okada M, et al: A phase 1/2 study of bosutinib in Japanese
adults with Philadelphia chromosome-positive chronic myeloid
leukemia. Int J Hematol. 101:154–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Strati P, Kantarjian H, Thomas D, O'Brien
S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E,
Quintas-Cardama A, et al: HCVAD plus imatinib or dasatinib in
lymphoid blastic phase chronic myeloid leukemia. Cancer.
120:373–380. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marin D, Bazeos A, Mahon FX, Eliasson L,
Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K,
et al: Adherence is the critical factor for achieving molecular
responses in patients with chronic myeloid leukemia who achieve
complete cytogenetic responses on imatinib. J Clin Oncol.
28:2381–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cortes J, Lipton JH, Rea D, Digumarti R,
Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE,
et al: Phase 2 study of subcutaneous omacetaxine mepesuccinate
after TKI failure in patients with chronic-phase CML with T315I
mutation. Blood. 120:2573–2580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pemovska T, Johnson E, Kontro M, Repasky
GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K,
et al: Axitinib effectively inhibits BCR-ABL1(T315I) with a
distinct binding conformation. Nature. 519:102–105. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Donato NJ, Wu JY, Stapley J, Gallick G,
Lin H, Arlinghaus R and Talpaz M: BCR-ABL independence and LYN
kinase overexpression in chronic myelogenous leukemia cells
selected for resistance to STI571. Blood. 101:690–698. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ptasznik A, Nakata Y, Kalota A, Emerson SG
and Gewirtz AM: Short interfering RNA (siRNA) targeting the Lyn
kinase induces apoptosis in primary, and drug-resistant,
BCR-ABL1(+) leukemia cells. Nat Med. 10:1187–1189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu Y, Liu Y, Pelletier S, Buchdunger E,
Warmuth M, Fabbro D, Hallek M, Van Etten RA and Li S: Requirement
of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced
B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat
Genet. 36:453–461. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Y, Swerdlow S, Duffy TM, Weinmann R,
Lee FY and Li S: Targeting multiple kinase pathways in leukemic
progenitors and stem cells is essential for improved treatment of
Ph+ leukemia in mice. Proc Natl Acad Sci USA. 103:16870–16875.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Larson RA: Is there a best TKI for chronic
phase CML? Blood. 126:2370–2375. 2015. View Article : Google Scholar : PubMed/NCBI
|
